Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/74—Synthetic polymeric materials
  • A61K31/785—Polymers containing nitrogen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• One method of reducing the amount of bile acids that are reabsorbed and, thus, reducing serum cholesterol is the oral administration of compounds that sequester the bile acids and cannot themselves be absorbed.
• the sequestered bile acids are excreted.
• bile acid sequestration examples include various ion exchange polymers.
• One such polymer is cholestyramine, a copolymer of divinylbenzene and trimethylammoniummethyl styrene. It has been long recognized that this polymer is unpalatable, gritty, and constipatmg.
• various polymers have been suggested which are characterized by hydrophobic substituents and quaternary ammonium radicals substituted upon an a ine polymer backbone (Ahlers, et al. U.S. Patent 5,428,112 and 5,430,110 and McTaggart, et al, U.S. Patent 5,462,730, which are incorporated herein by reference). In some cases, these polymers have had disappointing efficacy and require complex processes for their manufacture.
• the invention relates to the unexpected discovery that a new class of ion exchange resins have improved bile salt sequestration properties.
• the polymers, or resins, employed in the invention comprise non-absorbable, and optionally cross- linked polydiallylamines.
• the polydiallylamines of the invention are characterized bv one or more monomeric units of the formulae:
• the polymer can be characterized by the substantial absence of one or more alkylated amine monomers and/or the substantial absence of one or more trialkylammonium alkyl groups.
• the polymer is crosshnlced by means of a multifunctional crosslinking agent.
• the polymer can also be characterized as being linear or branched.
• the invention provides an effective treatment for removing bile salts from a patient (and thereby reducing the patient's cholesterol level).
• the invention also provides for the use of the polymers described herein in therapy or for the manufacture of a medicament for the treatment of hypercholesterolemia or for bile acid sequestration.
• the invention provides a method for removing bile acids from a patient comprising administering to the patient a therapeutically effective amount of a polymer characterized by a diallylamine monomer, or repeat unit.
• a therapeutically effective amount refers to an amount which is sufficient to remove a significant quantity of bile acids from the patient and, thus, to lower the serum cholesterol level of the patient.
• the patient can be an animal, for example, a mammal, or a human.
• the polymers employed in the invention comprise non- absorbable, optionally cross-linked polydiallylamines characterized by the fo ⁇ nula above.
• the polymers can be characterized by the substantial absence of substituted or unsubstituted alkyl substituents on the amino group of the monomer, such as obtained in the alkylation of an amine polymer. That is, the polymer can be characterized in that the polymer is substantially free of alkylated amine monomers.
• the polymer can be a homopolymer or a copolymer. Where copolymers are manufactured with a diallylamine monomer, the comonomers are preferably inert, non-toxic and/or possess bile acid sequestration properties.
• additional comonomers include substituted and unsubstituted acrylate, substituted and unsubstituted acrylamide, substituted and unsubstituted methacrylate, substituted and unsubstituted methacrylamide, allylamine, triallylamine, allyl alcohol, substituted and unsubstituted vinyl amine and substituted and unsubstituted vinyl alcohol.
• the additional monomer is sulfur dioxide.
• the monomers are aliphatic.
• the polymer is a homopolymer, i.e. a homopolydiallylamine.
• the polymer is rendered water-insoluble by branching and/or crosslinking.
• the cross-linking agent can be characterized by functional groups which react with the amino group of the monomer.
• the crosslinking group can be characterized by two or more vinyl groups which undergo free radical polymerization with the amine monomer.
• Suitable multifunctional co-monomers include triallylamine, tetraallyleammonium salts, bis(diallylamine)s (such as alkylene bis(diallylamine)s), diacrylates, triacrylates and tetraacrylates, dimethacrylates, diacrylamides, diallylacrylamide and di(methacrylamides).
• suitable multifunctional monomers include polyvinylarenes, such as divinylbenzene.
• the polymer can alternatively be crosslinked by bridging units which link amino groups on adjacent polymer strands.
• Suitable bridging units include straight chain or branched, substituted or unsubstituted alkylene groups, diacylalkylene groups, diacylarene groups and alkylene bis(carbamoyl) groups.
• Suitable bridging units include -(CH 2 ) n -, wherein n is an integer from about 2 to about 20; -CH 2 -CH(OH)-CH 2 -; -C(0)CH 2 CH 2 C(O)-; -CH 2 -CH(OH)-0-(CH 2 ) n -O- CH(OH)-CH 2 -, wherein n is 2 to about 4; -C(0)-(C 6 H 2 (COOH) 2 )-C(O)- and - C(0)NH(CH 2 ) p NHC(0)-, wherein p is an integer from about 2 to about 20.
• crosslinking agents examples include acryloyl chloride, epichlorohydrin, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, and dimethyl succinate.
• a preferred crosslinking agent is epichlorohydrin because of its high availability and low cost.
• Epichlorohydrin is also advantageous because of it's low molecular weight and hydrophilic nature, increasing the water-swellability of the polyamine.
• the level of crosslinking makes the polymers insoluble and substantially resistant to absorption and degradation, thereby limiting the activity of the polymer to the gastrointestinal tract.
• the compositions are non-systemic in their activity and will lead to reduced side-effects in the patient.
• the crosslinking agent is present in an amount from about 0.5-50% (more preferably about 0.5-30% and most preferably about 2-20%) by weight, based upon total weight of monomer plus crosslinking agent.
• polymers of use in the present method are, preferably, of a molecular weight which enables them to reach and remain in the gastrointestinal tract for a sufficient period of time to bind a significant amount of one or more bile acids. These polymers should, thus, be of sufficiently high molecular weight to resist, partially or completely, absorption from the gastrointestinal tract into other regions of the body. The resulting polymer/bile salt - complex should then be excreted from the body. Suitable linear (non-crosslinked) polymers have molecular weights which range from about 2,000 Daltons to about 500,000 Daltons, preferably from about 5,000 Daltons to about 150,000 Daltons. Crosslinked polymers, however, are not generally characterized by molecular weight. The crosslinked polymers discussed herein should be sufficiently crosslinked to resist adsorption from the gastrointestinal tract.
• the polymer can be administered in the form of a salt, or as a partial salt.
• salt it is meant that the nitrogen groups in all or some of the repeat units are protonated to create a positively charged nitrogen atom associated with a negatively charged counterion.
• the anionic counterions can be selected to minimize adverse effects on the patient, as is more particularly described below.
• counterions examples include Cl ⁇ Br ⁇ CH 3 OS0 3 ' , HS0 4 ⁇ SO " , nitrate, HC0 3 " ,C0 3 2 --acetate, lactate, phosphate, hydrophosphate, methanesulfonate, fumarate, malate, pyruvate, malonate, benzoate, glucuronate, oxalate, acetylglycinate, succinate, propionate, butyrate, ascorbate, citrate, tartrate, maleate, folate, an amino acid derivative, a nucleotide, a lipid, or a phospholipid.
• the counterions can be the same as, or different from, each other.
• the reaction product can contain two different types of counterions.
• the polymers according to the invention can be administered orally to a patient in a dosage of about 1 mg/lcg/day to about 10 g/kg/day, preferably between about 1 mg/lcg/day to about 200 mg/lcg/day; the particular dosage will depend on the individual patient (e.g., the patient's weight and the extent of bile salt removal required).
• the polymer can be administered either in hydrated or dehydrated form, and can be flavored or added to a food or drink, if desired, to enhance patient acceptability. Additional ingredients such as other bile acid sequestrants, drugs for treating hypercholesterolemia, atherosclerosis or other related indications, or inert ingredients, such as artificial coloring agents can be added as well.
• suitable forms for administration include pills, tablets, capsules, and powders (e.g., for sprinkling on food).
• the pill, tablet, capsule, or powder can be coated with a substance capable of protecting the composition from disintegration in the esophagus but will allow disintegration of the composition in the stomach and - mixing with food to pass into the patient's small intestine.
• the polymer can be administered alone or in combination with a pharmaceutically acceptable carrier, diluent or excipient substance, such as a solid, liquid or semi-solid material.
• Suitable carriers, diluents and excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, alginates, tragacanth, gelatin, calcium silicate, cellulose e.g., magnesium carbonate or a phospholipid with which the polymer can form a micelle.
• Polymers of use in the present method can be prepared using techniques known in the art of polymer synthesis (see for example, Shalaby et al, ed., Water- Soluble Polymers, American Chemical Society, Washington D.C. (1991)).
• the appropriate monomer(s) can be polymerized by methods known in the art, for example, via a free radical addition process.
• the polymerization mixture includes a free-radical initiator, such as a free radical initiator selected from among those which are well known in the art of polymer chemistry.
• Suitable free- radical initiators include azobis(isobutyronitrile), azobis(4-cyanovaleric acid), azobis(amidinopropane) dihydrochloride, potassium persulfate, ammonium persulfate and potassium hydrogen persulfate.
• the free radical initiator is preferably present in the reaction mixture in an amount ranging from about 0.1 mole percent to about 5 mole percent relative to the monomer.
• the polymer can be crosslinked, for example, by including a multifunctional co-monomer as the crosslinlcing agent in the reaction mixture.
• a multifunctional co- monomer can be incorporated into two or more growing polymer chains, thereby crosslinking the chains.
• Suitable multifunctional co-monomers include those discussed above.
• the polymers can also be crosslinked subsequent to polymerization by reacting the polymer with one or more crosslinking agents having two or more functional groups, such as electrophilic groups, which react with amine groups to form a covalent bond.
• Crosslinlcing in this case can occur, for example, via nucleophilic attack of the polymer amino groups on the electrophilic groups. This results in the formation of a bridging unit which links two or more amino nitrogen atoms from different polymer strands.
• Suitable crosslinking agents of this type include compounds having two or more groups selected from among acyl-X, epoxide, and alkyl-X, wherein X is a suitable leaving group, such as a halo, tosyl, mesyl, acyl or glycidyl group.
• X is a suitable leaving group, such as a halo, tosyl, mesyl, acyl or glycidyl group.
• Examples of such compounds include epichlorohydrin, succinyl dichloride, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, pyromellitic dianhydride and dihaloalkanes.
• the crosslinking agent can also be an ⁇ , ⁇ -alkylene diisocyanate, for example OCN(CH 2 ) p NCO, wherein p is an integer from about 2 to about 20.
• the polymer can also be crosslinked using a crosslinking agent which incorporates one functional group which incorporates into the polymerizing chain and a second functional group which can react with amine groups in a second polymer chain.
• a crosslinking agent which incorporates one functional group which incorporates into the polymerizing chain and a second functional group which can react with amine groups in a second polymer chain. Examples include glycidyl methacrylate, glycidyl acrylate, acryloyl chloride, methacryloyl chloride, 3-bromopropylacrylate, 3-bromopropylmethyl- diallylammonium chloride, and 3-chloropropyldiallylamine.
• Concentrated hydrochloric acid (507.0 g; 37%) was charged to a 5L, 3-neck round bottomed flask and agitated with a mechanical stirrer. The flask was cooled to ⁇ 5°C with an ice bath. Diallylamine (635.0 ml) was added dropwise to the stirring hydrochloric acid over a three hour period using an addition funnel capped with a pierced rubber septum. The stirring solution temperature was maintained at ⁇ 10°C. After the addition was completed, the ice bath was removed and the mixture was allowed to warm to room temperature. Concentrated hydrochloric acid (7.3 g) was added to the solution. Water (368.7 g) was added to the solution and it was allowed to sit overnight.
• 2,2'-Azobis[2-amidinopropane]dihydrochloride (6.87 g) was added as a 20% aqueous solution. The solution was stirred and heated for another 16 hours, then cooled to room temperature. Sodium hydroxide (53.8 g) was dissolved in H 2 0 (2156 mL). The polydiallylamine-HCl solution was then added to the sodium hydroxide solution and agitated with a mechanical stirrer until dissolved. Concentrated hydrochloric acid (49.8 g; 37%) was added.
• a solution of 39.3 g of an aqueous solution (68 wt%) of diallylammonium hydrochloride, 5.3 g of an aqueous solution (73 wt%)of triallylamine hydrochloride and 0.9 g of 2,2'-azobis(2-amidinopropane)dihydrochloride was bubbled with a slow stream of nitrogen for 30 minutes. While stirring, this reaction mixture was added to a solution of 7 g of polyvinylacetate in 300 mL of toluene. The resulting mixture was stirred at room temperature for 45 minutes under nitrogen atmosphere. While stirring, the temperature of the reaction mixture was raised to 60 C and was held at this temperature for 24 hours.
• the reaction mixture was allowed to cool to room temperature and the polymer particles were collected by filtration. While in the funnel, the filtered particles were successively washed with 300 mL of toluene and 500 mL of methanol. The polymer particles were suspended in 500 mL of methanol, stirred for 50 minutes, and filtered. Subsequently, the particles were suspended in 400 mL of deionized water, stirred for 30 minutes and filtered. The filtered particles were dried at 60 C for 24 hr to yield 15 g of the polymer.
• Example 1 The polymer solution of Example 1 was crosslinked at 30 mole % as follows:
• Epichlorohydrin (31.61 mL) was added to 900.0 g of the neutralized polymer solution in a glass beaker, agitated with a magnetic stirrer and covered with polyvinyl film. The gel was allowed to cure for 22 hours. The solid gel was then ground using a Kitchen Aid grinder. The ground polymer was washed in a static bed manner using a large plastic Buchner funnel lined with filter paper. A second piece of filter paper, perforated with holes, was placed on top of the polymer cake to prevent disturbing the cake when adding wash water. Fresh deionized H 2 O(14 L) " was added to the top of the cake and drained under vacuum. The washed polymer was then transferred to glass drying trays and dried in a 60° C forced air oven for several days. The final dry weight was 176.2 g.
• Example 3 Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 20 mole %. Epichlorohydrin (21.07 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 163.3 g.
• Example 3 Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 10 mole %. Epichlorohydrin (10.54 mL) was added to 900.0 g of the neutralized polymer solution. The final dry v/eight was 164.2 g.
• Example 3 Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 4.5 mole %. Epichlorohydrin (4.74 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 176.2 g.
• Example 7 Copolymer of Diallylamine and Methyl enebisacrylamide
• Example 10 Copolymer of Diallylamine, a Functionalized Acrylic Ester and an Acrylic Ester Cross-linking Monomer
• diallylammonium chloride (14.7 g of 68%> aqueous)
• 2- hydroxyethylmethacrylate (9.76 g)
• ethyleneglycol dimethacrylate (2.97 g)
• MeOH 25 mL
• 2,2'-azobis(2-amidinopropane) dihydrochloride (0.07 g of an 18.8% aqueous solution) was heated at 65 °C under a nitrogen atmosphere for 20 hours.
• the resulting material was suspended in methanol (500 mL), stirred for 15 minutes and filtered.
• the polymer was similarly washed three times with water (500 mL).
• Example 11 Copolymer of Diallylamine, a Functionalized Acrylic Ester and an Acrylic Ester Cross-linking Monomer
• diallylammonium chloride 22.06 g of a 68% aqueous solution
• tetrahydrofurfuryl methacrylate (18.72 g
• ethyleneglycol dimethacrylate (4.36 g)
• 2,2'-azobis(2-amidinopropane) dihydrochloride (2.03 g of an 18.8% aqueous solution) was heated at 65 °C under a nitrogen atmosphere for 24 hours.
• the resulting material was suspended in methanol (300 mL), stirred 15 minutes and filtered. This methanol wash and filtration was repeated twice more.
• the polymer was similarly washed three times with water (500mL).
• the material was suspended in water (500 mL) and this mixture was acidified with concentrated HCl to pH 2.0. Filtration, and drying at 60° C in a forced-air oven gave 19.9 g of a solid.
• Example 12 Copolymer of Diallylamine and Glycidylmefhacrylate
• a solution of diallylammoniium chloride (29.42 g of a 68% aqueous solution), glycidylmethacrylate (2.13 g), MeOH (25 mL), and 2,2'-azobis(2- amidmopropane) dihydrochloride (1.18 g of an 18.8% aqueous solution) was heated at 65 °C under a nitrogen atmosphere for 12 hours. After cooling to room temperature, methanol (25 mL) was added and the pH of the solution was adjusted to 10 with the addition of 50% aqueous NaOH, and allowed to stir at room temperature. The reaction solution turned to a solid mass after about 2 hours, and was allowed to stand for 22 hours.
• Example 13 Copolymer of Allylamine, Diallylamine, Triallylamine and a Bis(diallylamino)alkylene salt
• allylammonium chloride (25.0 g of a 60% aqueous solution), diallylammonium chloride (66.81 g of a 67% aqueous solution), triallylammonium chloride (40.87 g of a 68% aqueous solution), l,6-bis(diallylmethylammoniium) " hexane dibromide (5.0 g), and 2,2'-azobis(2-amidinopropane) dihydrochloride (4.28 g of a 20% aqueous solution), was heated at 55 °C under a nitrogen atmosphere for 18 hours and at 80 °C for 2 hours.
• Example 15 Copolymer of Allylamine, Diallylamine and a Bis(diallylamino) alkylene
• allylammonium chloride 27.36 g of a 57% aqueous solution
• diallylammonium chloride 66.48 g of a 67% aqueous solution
• l,6-bis(diallyl- methylammonium) hexane dibromide (10.0 g)
• 2,2'-Azobis(2-amidinopropane) dihydrochloride (3.01 g of a 20% aqueous solution(, was heated at 55°C under a nitrogen atmosphere for 36 hours.
• crosslinked polydiallylamine is a highly potent bile acid sequestrant, with in vivo activity greater than current commercial products, Colestipol and Cholestyramine.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Diabetes (AREA)
• Epidemiology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Heart & Thoracic Surgery (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Gastroenterology & Hepatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Publications (2)

Family

ID=25508662

Family Applications (1)

Country Status (20)

Cited By (13)

Families Citing this family (45)

Family Cites Families (89)

• 1997
  • 1997-11-05 US US08/964,536 patent/US6083497A/en not_active Expired - Lifetime
• 1998
  • 1998-03-11 AR ARP980105512A patent/AR013742A1/es not_active Application Discontinuation
  • 1998-10-23 ZA ZA989673A patent/ZA989673B/xx unknown
  • 1998-10-26 HU HU0004279A patent/HUP0004279A3/hu unknown
  • 1998-10-26 KR KR1020007004892A patent/KR20010031822A/ko not_active Withdrawn
  • 1998-10-26 BR BR9813961-4A patent/BR9813961A/pt not_active Application Discontinuation
  • 1998-10-26 PL PL98340296A patent/PL340296A1/xx unknown
  • 1998-10-26 AU AU13646/99A patent/AU746876B2/en not_active Expired
  • 1998-10-26 JP JP2000518655A patent/JP4649039B2/ja not_active Expired - Lifetime
  • 1998-10-26 EP EP98957370A patent/EP1028717B1/en not_active Expired - Lifetime
  • 1998-10-26 CA CA002309027A patent/CA2309027C/en not_active Expired - Lifetime
  • 1998-10-26 AT AT98957370T patent/ATE235236T1/de active
  • 1998-10-26 WO PCT/US1998/022605 patent/WO1999022721A2/en not_active Ceased
  • 1998-10-26 NZ NZ504216A patent/NZ504216A/xx not_active IP Right Cessation
  • 1998-10-26 CN CN98810752A patent/CN1278180A/zh active Pending
  • 1998-10-26 ES ES98957370T patent/ES2196625T3/es not_active Expired - Lifetime
  • 1998-10-26 IL IL13585898A patent/IL135858A0/xx unknown
  • 1998-10-26 DE DE69812681T patent/DE69812681T2/de not_active Expired - Lifetime
  • 1998-11-03 TW TW087118239A patent/TW453878B/zh not_active IP Right Cessation
• 1999
  • 1999-05-13 US US09/311,103 patent/US6365186B1/en not_active Expired - Lifetime
  • 1999-05-13 US US09/311,402 patent/US6264938B1/en not_active Expired - Lifetime
• 2000
  • 2000-03-09 US US09/521,975 patent/US6248318B1/en not_active Expired - Lifetime
  • 2000-04-27 NO NO20002172A patent/NO20002172L/no not_active Application Discontinuation
• 2001
  • 2001-12-19 US US10/025,184 patent/US7638524B2/en not_active Expired - Fee Related
• 2009
  • 2009-11-09 US US12/590,511 patent/US20100266526A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events